- Home
- ANIP vs MDXG Comparison
ANIP vs MDXG Comparison
Compare ANIP & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- MDXG
- Stock Information
- Founded
- ANIP 2001
- MDXG 2006
- Country
- ANIP United States
- MDXG United States
- Employees
- ANIP N/A
- MDXG N/A
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ANIP Health Care
- MDXG Health Care
- Exchange
- ANIP Nasdaq
- MDXG Nasdaq
- Market Cap
- ANIP 1.2B
- MDXG 1.3B
- IPO Year
- ANIP N/A
- MDXG N/A
- Fundamental
- Price
- ANIP $58.59
- MDXG $8.57
- Analyst Decision
- ANIP Buy
- MDXG Strong Buy
- Analyst Count
- ANIP 7
- MDXG 5
- Target Price
- ANIP $77.33
- MDXG $12.00
- AVG Volume (30 Days)
- ANIP 171.1K
- MDXG 617.6K
- Earning Date
- ANIP 02-27-2025
- MDXG 02-26-2025
- Dividend Yield
- ANIP N/A
- MDXG N/A
- EPS Growth
- ANIP N/A
- MDXG N/A
- EPS
- ANIP N/A
- MDXG 0.52
- Revenue
- ANIP $555,456,000.00
- MDXG $342,804,000.00
- Revenue This Year
- ANIP $25.54
- MDXG $9.56
- Revenue Next Year
- ANIP $20.95
- MDXG $9.19
- P/E Ratio
- ANIP N/A
- MDXG $16.49
- Revenue Growth
- ANIP 23.60
- MDXG 10.93
- 52 Week Low
- ANIP $52.50
- MDXG $5.47
- 52 Week High
- ANIP $70.81
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ANIP 55.72
- MDXG 41.31
- Support Level
- ANIP $57.08
- MDXG $8.29
- Resistance Level
- ANIP $60.99
- MDXG $9.30
- Average True Range (ATR)
- ANIP 1.56
- MDXG 0.30
- MACD
- ANIP 0.08
- MDXG -0.04
- Stochastic Oscillator
- ANIP 61.54
- MDXG 27.10
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.